Preliminary Results of the Multicenter Trial GPOH-HD 95 for the Treatment of Hodgkin’s Disease in Children and Adolescents: Analysis and Outlook

2003 ◽  
Vol 215 (3) ◽  
pp. 139-145 ◽  
Keyword(s):  
Children And Adolescents ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Multicenter Trial ◽  
Preliminary Results

The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage ia through iib hodgkin's disease: Preliminary results

1988 ◽  
Vol 14 (4) ◽  
pp. 683-692 ◽  
Author(s):  
Lillian M. Fuller ◽  
Fredrick B. Hagemeister ◽  
Luceil B. North ◽  
Peter McLaughlin ◽  
William S. Velasquez ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Preliminary Results ◽  
Stage Ia ◽  
Lung Irradiation

Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group

2004 ◽  
Vol 22 (12) ◽  
pp. 2424-2429 ◽  
Author(s):  
Henning Bredenfeld ◽  
Jeremy Franklin ◽  
Lucia Nogova ◽  
Andreas Josting ◽  
S. Fries ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Pulmonary Toxicity ◽  
Hodgkin’S Disease ◽  
Maximum Tolerated Dose ◽  
Multicenter Trial ◽  
Advanced Stage ◽  
Dose Escalation Study ◽  
Starting Dose ◽  
Lymphoma Study Group

Purpose To investigate a new effective, nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin's disease (HD). Patients and Methods Patients in clinical stages IIB with risk factors III and IV were enrolled in this nonrandomized, multicenter trial aimed at defining the maximum-tolerated dose of gemcitabine within a modified escalated BEACOPP regimen. Gemcitabine was given at a starting dose of 800 mg/m2 on days 1 and 4 of each cycle. Results Twenty-seven patients (eight female, 19 male) were enrolled with a median age of 33 years (range, 19 to 65 years). Due to a higher than expected hematotoxicity, the day-4 application of gemcitabine was omitted after 14 patients were included and 59 cycles were given. A total of eight patients developed lung toxicity, mainly pneumonitis (six of eight), which led to the termination of the study. With a median follow-up of 27 months, 25 patients are in continuing complete remission. Conclusion The substitution of etoposide by gemcitabine in the escalated BEACOPP schema is not feasible and leads to severe pulmonary toxicity. This toxicity is probably related to the concomittant application of gemcitabine and bleomycin.

Sign in / Sign up

Export Citation Format

Share Document